Bevacizumab for metastatic XXXX : does @entity1 BMI influence survival?

@entity1 @entity6 @entity5 @entity3 @entity694 @entity204 @entity1349
UNASSIGNED: Adipose tissue is considered to have endocrine properties, including factors that are considered to have angiogenic activity. The current study aimed to evaluate whether there was a difference in the efficacy of bevacizumab for metastatic @entity694 @entity1 according to their BMI (kg/m). A retrospective review of the medical records of consecutive @entity1 who were treated with bevacizumab from diagnosis for metastatic @entity694 between 2005 and 2011 was carried out. Data extracted from medical files included demographics, height, weight, comorbidities, treatment protocols, time @entity5 ( @entity5 ), and time of @entity204 . Variables were further evaluated with respect to @entity5 and @entity1349 ( @entity1349 ). The final analysis included 184 @entity1 . The median @entity5 was 11.7 months and the median survival was 27.6 months. Chemotherapy dose reduction [P>0.001, hazard ratio (HR)=0.6, 95% confidence interval (CI) 0.4-0.8] and male sex (P=0.03, HR=0.7, 95% CI 0.5-1.0) predicted @entity5 . Multivariate analysis indicated that @entity3 at initial presentation and/or @entity6 were associated with worse @entity1349 : the median @entity1349 for @entity6 was 20 versus 28.3 months for @entity1 without @entity6 (P=0.008, HR=2, 95% CI 1.2-3.4) and 23 months for @entity1 with @entity3 at initial presentation versus 31.4 months for recurrent disease (P=0.008, HR=1.6, 95% CI 1.1-2.2). No differences were found for different BMIs subdivided into groups with respect to @entity1349 (P=0.84) or @entity5 (P=0.75). Our study did not show that bevacizumab is less effective in @entity1 with a high BMI. It did show that @entity6 and/or @entity3 at initial diagnosis are associated with a poorer outcome.
